環能國際(01102.HK)擬收購“天使元素”知識產權及註冊商標
格隆匯11月20日丨環能國際(01102.HK)發佈公告,2019年11月20日,公司或其指派的任何附屬公司作為買方與北京國潤東方生物科技有限公司就潛在收購事項訂立一份無法律約束力框架協議。框架協議無法律約束力,且須待簽署正式協議後作實。涉及潛在收購事項正式協議條款尚未釐定。
根據框架協議,賣方擬出售其擁有的“天使元素”(用於植物種植及土壤改良)的知識產權及註冊商標予買方。有關潛在收購事項將由買方安排促成發行公司普通股股份予賣方作為代價,最終代價將載於正式協議內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.